Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Cetrelimab |
Trade Name | |
Synonyms | JNJ63723283|JNJ 63723283|JNJ-63723283 |
Drug Descriptions |
Cetrelimab (JNJ-63723283 ) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28943093). |
DrugClasses | Immune Checkpoint Inhibitor 155 PD-L1/PD-1 antibody 105 |
CAS Registry Number | 2050478-92-5 |
NCIT ID | C129448 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Apalutamide + Cetrelimab | Apalutamide Cetrelimab | 0 | 2 |
Cabazitaxel + Carboplatin + Cetrelimab | Cabazitaxel Carboplatin Cetrelimab | 0 | 1 |
Cetrelimab | Cetrelimab | 0 | 2 |
Cetrelimab + Daratumumab | Cetrelimab Daratumumab | 0 | 1 |
Cetrelimab + Erdafitinib | Cetrelimab Erdafitinib | 0 | 1 |
Cetrelimab + JNJ-78278343 | Cetrelimab JNJ-78278343 | 0 | 1 |
Cetrelimab + Niraparib | Cetrelimab Niraparib | 0 | 2 |
Cetrelimab + TAR-200 | Cetrelimab TAR-200 | 0 | 4 |